AzTrials
AzTrials

Tetralogy of FallotNCT04581668

Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease

A study testing Two ventilation periods with two different modes: conventional ventilation followed by NAVA. in people with Tetralogy of Fallot and Hypoplastic Left Heart Syndrome, run by St. Justine's Hospital at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Positive intra-thoracic pressures induced by mechanical ventilation can negatively impact right heart hemodynamics by restricting systemic venous return and increasing right ventricular afterload. Read more about this study

Who is it for?
Ages 1 day to 18 years
What is being tested?
Two ventilation periods with two different modes: conventional ventilation followed by NAVA.
How many people
30 participants
Where
1 siteCanada
Study dates
5 Oct 2020to 3 Feb 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 day to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • admission to the pediatric intensive care unit:
  • after Glenn, Fontan, Fallot Tetralogy surgery
  • or after other types of surgery with risk of post-operative occurence of right ventricular failure or low lung output
  • invasive ventilation scheduled for at least 2 hours after admission

Who cannot join

  • Contraindication to placement of a nasogastric NAVA tube
  • History of significant focal brain injury (infarction or hemorrhage)
  • Bilateral phrenic paralysis
  • Extubation in operating room or planned to be within the hour,
  • Patient with open chest, uncontrolled shock, need for neuromuscular blockade. Note that for these criteria, the patient may become eligible when these criteria are resolved.
  • Patients for whom an acute care limitation order is in place.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • St. Justine's Hospital

    Montreal, Quebec, H3T 1C5

Other trials in Canada

About this study

Positive intra-thoracic pressures induced by mechanical ventilation can negatively impact right heart hemodynamics by restricting systemic venous return and increasing right ventricular afterload. These consequences may be detrimental in patients with a restrictive right ventricular physiology and in patients with single ventricle physiology. NAVA (Neurally Adjusted Ventilatory Assist) ventilation decreases intra thoracic pressures compared to conventional ventilation modes. Brain perfusion is both a hemodynamic indicator and a prognostic factor in cardiac postoperative care. Diffuse Correlation Spectroscopy (DCS) coupled with Near Infrared Spectroscopy (NIRS) is a new technology that allows monitoring, in addition to brain tissue oxygenation, changes in brain blood flow.

This physiological study aims to evaluate the impact of NAVA mode ventilation on cerebral and systemic hemodynamics in post-operative cardiac surgery patients with preload dependant right ventricle or with passive venous return to the lungs . This prospective cross-over study will include 30 patients.

Read more

Once stabilized in intensive care, patients will undergo 2 periods of ventilation in conventional mode and NAVA mode.

For each period the following information will be collected: changes in cerebral blood flow and cerebral oxygenation, hemodynamic parameters including cardiac output and oxygen transport and ventilatory parameters.

Read the detailed description
  1. Scientific context In post-operative cardiac surgery, invasive ventilation is often necessary, but the induced positive intra thoracic pressures can be detrimental to hemodynamics via several mechanisms: decrease in venous return, increase in pulmonary vascular resistance and increase in the afterload of the right ventricle. This effect is particularly problematic in patients with a restrictive right ventricle, who are preload dependent, and in patients with cavo pulmonary connections for single ventricle palliation. In these patients, decreasing ventilator positive pressure improves cardiac output and cerebral oxygenation. However, very early extubation is not always possible or safe, and it is therefore essential to optimize mechanical ventilation in order to minimize its hemodynamic consequences. In adults, ventilation in NAVA (Neurally Adjusted Ventilatory Assist) mode, regardless of the level of assistance, allows the preservation of intra thoracic pressure variations characteristic of spontaneous ventilation and limits the impact of ventilation on right ventricular ejection. In children, inspiratory and mean pressures are also lower in NAVA compared to conventional ventilation. Assessment of brain oxygenation and perfusion in cardiovascular resuscitation is important both as a hemodynamic parameter and as a neurological prognostic factor. An innovative non-invasive tool, Diffuse Correlation Spectroscopy coupled with Near Infrared Spectroscopy (DCS-NIRS), allows the non-invasive evaluation of both cerebral oxygenation and variations in cerebral blood flow.
  2. Hypothesis and objectives The hypothesis is that the NAVA ventilation mode, which generates lower intra thoracic pressures than conventional ventilation modes, will improve cerebral hemodynamics, cardiac output, and oxygen transport of at-risk patients in the post-operative cardiac surgery setting compared with conventional ventilation. Main objective: In pediatric patients following cardiac surgery with risk of right ventricular diastolic dysfunction or passive pulmonary venous return (including Glenn, hemi-Fontan, Fontan, and Tetralogy of Fallot surgery), investigators will evaluate the impact of NAVA ventilation on:
  • cerebral perfusion: cerebral blood flow (mm2/s) measured by DCS.
  • cerebral oxygenation: cerebral tissue saturation (%) and regional cerebral O2 extraction (OEF, measured by NIRS-DCS). Secondary objective: In pediatric post-operative cardiac surgery patients with risk of restrictive right ventricle or passive pulmonary venous return (including Glenn, hemi-Fontan, Fontan, and Tetralogy of Fallot type surgery), investigators will compare the impact of conventional ventilation to NAVA mode on:
  • Brain regional O2 consumption extracted from NIRS-DCS measurements
  • Systemic hemodynamics, including cardiac index, lactate level, central venous oxygen saturation (ScvO2), and oxygen transport
  • Ventilation parameters
  • Comfort as measured by the COMFORT behavioural scale
  1. Methods

This is a prospective cross-over, single-center, physiological study to be conducted in the Pediatric Intensive Care Unit of CHU Sainte Justine (Montreal, Canada).

Two periods of 30 to 60 minutes in each of 2 ventilation modes will be compared: conventional ventilation mode (as prescribed by the treating team) and NAVA mode.

On admission to the PICU postoperatively, study patients will be fitted with a naso-gastric NAVA probe.

Before performing any study measurements, investigators will wait for patient stabilization, which is defined by:

  • absence of hemodynamically significant bleeding
  • stabilization of the ventilation parameters
  • stable inotrope dose

Study period ventilation will be set as follows:

  • conventional ventilation: ventilation as prescribed by the treating team will be continued. Usually, ventilation is in PRVC (pressure regulated volume control) mode with a tidal volume between 5 and 8 mL/kg, a peep between 4 and 5, a respiratory rate to aim for normocapnia, and FiO2 to aim for PaO2 between 100 and 150 mmHg.
  • NAVA Mode: NAVA level setting to target an Edi level between 3 and 20 V, tidal volume between 5 and 7 mL/kg, and no respiratory distress on physical examination. The trigger will be set at 0.5 V. The maximum pressure will be limited to 30 cmH2O. The PEEP level will not be changed from that prescribed by the treating physician.

To facilitate comparability of brain flow and oxygenation measurements, FiO2, NO concentration, inotrope dose, and sedation will be kept as stable as possible during these periods, at the discretion of the treating physician. Similarly, if possible, blood transfusions will not be administered during the study period.

During the two periods of ventilation, the following parameters will be recorded continuously:

  • ventilatory parameters: ventilator parameters according to the set mode: peak inspiratory pressure, mean airway pressure, PEEP, tidal volume, total and spontaneous minute ventilation, Edi level, FiO2, exhaled CO2 via volumetric capnography.
  • hemodynamic parameters: heart rate (HR), mean arterial pressure, systolic, diastolic, central venous pressure (CVP), left atrial pressure (LAP), type and dose of vasoactive medications received with calculation of the vasoactive-inotropic score.

In the second half of each period, investigators will perform:

  • a central arterial and venous blood gas and an arterial lactate measurement.
  • a measurement of cerebral blood flow by diffuse correlation spectroscopy and a measurement of cerebral regional tissue saturation and oxygen extraction. These measurements are done non-invasively and painlessly by applying a probe to the child's forehead for approximately 20 minutes.
  • a limited cardiac ultrasound for the calculation of cardiac output (CO).
  • calculation of urine output during the ventilation period.

In addition, for each patient, the following information will be collected:

  • age at the time of surgery
  • cardiac diagnosis
  • existence and quantification of aorto-pulmonary collaterals
  • preoperative medications
  • operative details: surgical procedure, duration of cardiopulmonary bypass, aortic cross-clamp duration, inotropes administered (and maximum dose).
  • result of the postoperative trans-esophageal cardiac echo (cardiac function, evaluation of repair, presence of residual anatomic lesions)
  • arterial and venous blood gases, lactate and haemoglobin levels prior to study ventilation periods
  • time interval between the end of cardiopulmonary bypass and the start of study measurements

The variables will be expressed in terms of mean standard deviation or median (interquartile), depending on the nature of their distribution. Because of the sample size, analysis of the differences between t variables during the 2 modes of ventilation will be done using the non-parametric Wilcoxon test (all the variables studied are of the continuous type). A value of p <0.05 will be considered significant.

For the calculation of sample size, investigators estimated, using the study by Huang et al, that the standard deviation of brain saturation would be 6%, and that the expected difference between the 2 ventilation modes would be at least 6%. To reach a power of 90% with an alpha risk set at 0.05, a minimum of 24 patients is required. Given the risk of loss of sight (e.g. technical difficulty in obtaining the main variable) and due to the heterogeneity of the patient population, we decided to aim to include 30 patients.

Note that no power calculation based on the variations in cerebral blood flow measured in spectroscopy was performed, because there was no preliminary data on the subject.

Approval from the Research Ethics Committee of Sainte Justine University Hospital and the University Medical Affairs Department was obtained. Written consent will be required from the parents.

Being tested
Two ventilation periods with two different modes: conventional ventilation followed by NAVA.
Keywords
PICU, congenital heart disease, NAVA, cardiopulmonary interaction
Medical subject headings
Tetralogy of Fallot, Hypoplastic Left Heart Syndrome, Univentricular Heart, Heart Defects, Congenital

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Two ventilation periods with two different modes: conventional ventilation followed by NAVA.Other

    The patients will be ventilated successively using conventional ventilation followed by NAVA for 30-60 minutes each.

    Echocardiography and blood gases will be performed at the end of each period. Vital signs and ventilatory parameters will be continuously collected.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Brain perfusion

    cerebral blood flow measured with diffuse correlation spectroscopy (mm2/s)

    Measured: 5 minute period at the end of each 60-minute ventilatory periods

  2. Brain oxygenation

    cerebral tissue saturation measured with near-infrared spectroscopy (%)

    Measured: median value of the continuous measurement during each of the two 60-minute ventilatory periods

  3. Brain oxygen extraction

    Cerebral tissue oxygen extraction measured with near-infrared spectroscopy (%)

    Measured: 5 minute period at the end of each 60-minute ventilatory periods

Secondary outcomes (10)
  1. Brain regional oxygen consumption

    Cerebral tissue oxygen consumption measured with near-infrared spectroscopy

    Measured: 5 minute period at the end of each 60-minute ventilatory periods

  2. Cardiac output

    Cardiac output measured using sub aortic time-velocity integral measured on cardiac ultrasound

    Measured: in the 10 minute period at the end of each 60-minute ventilatory periods

  3. Cardiac index

    Cardiac index measured using sub aortic time-velocity integral measured on cardiac ultrasound

    Measured: in the 10 minute period at the end of each 60-minute ventilatory periods

  4. Oxygen transport

    According to the following calculation: 1.34 x hemoglobin x SaO2 + 0.0031 x PaO2

    Measured: in the 10 minute period at the end of each 60-minute ventilatory periods

  5. Mean airway pressure (cmH2O)

    Mean airway pressure (cmH2O) extracted from the ventilator every 30 seconds

    Measured: median value of the continuous measurement during each of the two 60-minute ventilatory periods

  6. Tidal volume

    extracted from the ventilator every 30 seconds

    Measured: median value of the continuous measurement during each of the two 60-minute ventilatory periods

  7. Respiratory rate

    extracted from the ventilator every 30 seconds

    Measured: median value of the continuous measurement during each of the two 60-minute ventilatory periods

  8. Minute ventilation

    extracted from the ventilator every 30 seconds

    Measured: median value of the continuous measurement during each of the two 60-minute ventilatory periods

  9. Electrical activity of the diaphragm

    extracted from the ventilator every 30 seconds

    Measured: median value of the continuous measurement during each of the two 60-minute ventilatory periods

  10. PaO2/FiO2 ratio

    Ratio calculated at the end of each ventilation period, based on arterial blood gas

    Measured: Within the 10 minutes at the end of the two 60-minute ventilatory periods

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Oct 2020
  2. Study start5 Oct 2020
  3. Primary completion3 Feb 2026
  4. Study completion3 Feb 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Non-randomised
Intervention model
Crossover
Model description
A cross-over physiological study consisting of two distinct phases, each lasting 30 to 60 minutes.
Masking
None (open label)
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04581668
Sponsor's protocol ID
2021-2731
Status last verified
Sep 2026
First submitted
27 Sep 2020
Last updated
21 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Two ventilation periods with two different modes: conventional ventilation followed by NAVA. in people with Tetralogy of Fallot and Hypoplastic Left Heart Syndrome, run by St. Justine's Hospital at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Brain perfusion (time frame: 5 minute period at the end of each 60-minute ventilatory periods). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in